Project Grant R01CA285536
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$458K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Mayo Clinic Jacksonville to conduct research on generating synthetic lethality in glioblastoma using a novel non-muscle myosin II inhibitor, MT-125. The $607,634 award, spanning January 1, 2025 to December 31, 2029, aims to uncover the mechanisms for synergy between MT-125, signal transduction inhibitors, and radiation therapy to optimize the use of this therapeutic...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $678,879 to Cold Spring Harbor Laboratory to conduct research on epigenetic mechanisms that can re-establish tumor suppression in glioblastoma (GBM), the most common and deadly adult primary brain cancer. The key focus of the research is to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 can re-activate the p53 tumor...
This federal Project Grant award from the National Cancer Institute (93.395 - Cancer Treatment Research) provides funding to Brigham & Women's Hospital Inc. to develop and extensively test a novel cellular therapy platform for treating glioblastoma (GBM), a highly malignant brain tumor. The $417,858 award, effective January 7, 2025 through December 31, 2029, will support the development of engineered mesenchymal stem cells (MSCs) that release bi-specific T-cell engager (BiTE) molecules...
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to conduct research targeting glioblastoma stem cells. The research aims to leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to understand how aging promotes tumor growth through cell autonomous mechanisms and interactions with the microenvironment. The project will leverage spatial transcriptomics and...
This $639,004 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Mayo Clinic to evaluate a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The project aims to mitigate treatment-related lymphopenia, enhance immune response, and improve survival in glioblastoma patients. Key activities include collecting and analyzing pre- and post-treatment tumor and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), is focused on developing novel oncolytic virus-based immunotherapies for treating glioblastoma (GBM), a fatal form of brain cancer. The $627,061 award aims to determine if combining an oncolytic herpes simplex virus (oHSV) engineered to express interleukin-12 (G47-IL12) with agents inhibiting adenosine...
The federal Project Grant award R21CA284153, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), provides $402,401 to the Mayo Clinic Jacksonville to evaluate the role of the SPAK and OSR1 kinases in glioblastoma (GBM) chemotherapy resistance. The goal is to determine if inhibiting these kinases can enhance the efficacy of chemoradiotherapy for GBM, the most deadly brain cancer. The 2-year project will assess the therapeutic potential of a novel small...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $547,687 to support research on small molecule inhibitors of the SLIT2/ROBO signaling pathway as a novel therapeutic approach for glioblastoma, the most aggressive form of brain cancer. The key products and services to be delivered include: 1) Screening a chemical library to identify small molecule inhibitors of the SLIT2/ROBO interaction, 2) Validating the top hit compounds...
This $369,108 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) will support research by the Broad Institute, Inc. to investigate mechanisms of drug resistance in BRAF-mutant melanoma. The goal is to demonstrate that melanomas developing resistance to BRAF and MEK inhibitors can be sensitized to lethal MAPK pathway hyperactivation, potentially overcoming resistance and leading to tumor eradication. The research will employ...
The National Cancer Institute (NCI) awarded a $404,974 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University to investigate the potential of KIF20A as a therapeutic target for glioblastoma, an aggressive brain cancer. The two-year grant, effective July 1, 2024, aims to: Define the requirement for KIF20A, a mitotic kinesin, in early mitosis by examining the impact of KIF20A knockout on mitotic progression and factors that influence sensitivity to...